{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086624","form_type":"8-K","ticker":"ISPC","cik":"0001558569","company_name":"iSpecimen Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.290287+00:00","generated_at":"2026-06-12T13:22:05.522534+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iSpecimen Q2 revenue down 31% to $1.63M; net loss widens to $3.5M","bullets":["Revenue of $1.63M (Q2 2023), down 31% YoY from $2.34M; net loss $3.5M ($0.39 per share) vs $2.6M ($0.30) in Q2 2022.","Cash + investments $8.2M at June 30, down from $15.3M at Dec 31, 2022 due to operating spend and technology investments.","Unique customer organizations up 22% YoY to 534; supplier organizations up 7.5% to 230.","CEO cites industry-wide funding slowdown; backlog increased in Q2, expects stronger Q3 2023 results.","New growth initiatives: sequencing pilot complete, embedded coordinators at supplier sites, remnant line reboot."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086624","json":"https://secwatch.observer/filing/0001104659-23-086624.json","markdown":"https://secwatch.observer/filing/0001104659-23-086624.md","text":"https://secwatch.observer/filing/0001104659-23-086624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923086624/0001104659-23-086624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923086624/tm2322620d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T13:22:05.522534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65a957b912da400df288d50613354083146cc1e0","claim":"iSpecimen Inc. reported the six months ended June 30, 2023 results: revenue approximately $4.6 million, net income approximately $5.9 million, EPS $(0.66) per share.","evidence_excerpt":"both our top and bottom-line results,” concluded Curley. Q2 2023 Financial Results & Recent Operational Highlights · Revenue of $1.63 million for the three month period and $4.6 million for the six month period of 2023 compared to $2.34 million for the three month period and $4.9 million for the six month period of 2022. · Unique supplier organizations under","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923086624/0001104659-23-086624-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"approximately $4.6 million"},{"label":"Net income","value":"approximately $5.9 million"},{"label":"EPS","value":"$(0.66) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9e0ab8624e96c680802afcccf65db7387ef6dca7","claim":"iSpecimen Inc. reported second quarter of 2023 results: revenue approximately $1.63 million, net income approximately $3.5 million, EPS $(0.39) per share.","evidence_excerpt":"supplier and customer base, we expect to build both our top and bottom-line results,” concluded Curley. Q2 2023 Financial Results & Recent Operational Highlights · Revenue of $1.63 million for the three month period and $4.6 million for the six month period of 2023 compared to $2.34 million for the three month period and $4.9 million for the six month period of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923086624/0001104659-23-086624-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Revenue","value":"approximately $1.63 million"},{"label":"Net income","value":"approximately $3.5 million"},{"label":"EPS","value":"$(0.39) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}